AI assistant
Sending…
HAEMONETICS CORP — Director's Dealing 2019
Aug 12, 2019
31565_dirs_2019-08-12_b3930e0d-4e52-4b2d-9ca2-5c96f8c3fc83.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: HAEMONETICS CORP (HAE)
CIK: 0000313143
Period of Report: 2019-08-09
Reporting Person: Goldstein Dan (VP, Corporate Controller)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2019-08-09 | Common Stock | M | 475 | $93.52 | Acquired | 3264 | Direct |
| 2019-08-09 | Common Stock | S | 475 | $133.23 | Disposed | 2789 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2019-08-09 | Non-qualified Stock Option (Right to Buy) | $93.52 | M | 475 | Disposed | 2025-06-11 | Common Stock (475) | Direct |
Footnotes
F1: This number includes unvested restricted stock units previously reported.
F2: Option vests in annual increments of 25% beginning on the first anniversary of the date of grant.
More from HAEMONETICS CORP
Annual Report
2026
Jun 9
Proxy Solicitation & Information Statement
2026
Jun 9
Proxy Solicitation & Information Statement
2026
Jun 9
Regulatory Filings
2026
Jun 5
Regulatory Filings
2026
May 28
Annual Report
2026
May 20
Major Shareholding Notification
2026
May 13
Regulatory Filings
2026
May 7
Regulatory Filings
2026
May 1
Major Shareholding Notification
2026
Apr 30